Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients

Autoimmunity

Volumn 46, Issue 8, 2013, Pages 537-546

  Bozzolo, Enrica P ^a   Ramirez, Giuseppe A ^a   Bonavida, Giovanna ^a   Lanzani, Chiara ^b   Scotti, Raffaella ^a   Dell'Antonio, Giacomo ^c   Baldissera, Elena ^a   Canti, Valentina ^a   Manfredi, Angelo A ^a   Rovere Querini, Patrizia ^a   Sabbadini, Maria Grazia ^a  

^a Unit of Medicine and Clinical immunology   (Italy)

^b Division of Nephrology   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Drug related toxicity; Immunosuppression; Nephritistherapy; Overall survival; Renal function; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MESNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADULT; ADVERSE OUTCOME; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPLAN MEIER METHOD; LEGIONNAIRE DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEASLES; NEPHRITIS; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PNEUMONIA; REMISSION; TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887454148     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2013.817560     Document Type: Article

References (67)

1. Bastian, H. M., J. M. Roseman, G. McGwin Jr, et al. 2002. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 11: 152-160 (Pubitemid 34296930)
2. Isenberg, D., G. B. Appel, G. Contreras, et al. 2010. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49: 128-140
3. Ong, C., K. Nicholls, and G. Becker. 2011. Ethnicity and lupus nephritis: an Australian single centre study. Intern. Med. J. 41: 270-278
4. Siso, A., M. Ramos-Casals, A. Bove, et al. 2010. Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. Medicine. (Baltimore). 89: 300-307
5. Stewart, M., and M. Petri. 2000. Lupus nephritis outcomes: health maintenance organizations compared to non-health maintenance organizations. J. Rheumatol. 27: 900-902 (Pubitemid 30389744)
6. Croca, S. C., T. Rodrigues, and D. A. Isenberg. 2011. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology. (Oxford). 50: 1424-1430
7. Ward, M. M. 2009. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J. Rheumatol. 36: 63-67
8. Williams,W., L. A. Sargeant, M. Smikle, et al. 2007. The outcome of lupus nephritis in Jamaican patients. Am. J. Med. Sci. 334: 426-430 (Pubitemid 350306461)
9. Cervera, R., M. A. Khamashta, J. Font, et al. 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine. (Baltimore) 82: 299-308 (Pubitemid 37229465)
10. Faurschou, M., L. Dreyer, A. L. Kamper, et al. 2010. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care. Res. (Hoboken) 62: 873-880
11. Zonana-Nacach, A., P. Yanez, F. J. Jimenez-Balderas, and A. Camargo-Coronel. 2007. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus. 16: 997-1000
12. Clarke, A. E., P. Panopalis, M. Petri, et al. 2008. SLE patients with renal damage incur higher health care costs. Rheumatology. (Oxford) 47: 329-333 (Pubitemid 351267201)
13. Pontillo, A., M. Girardelli, A. J. Kamada, et al. 2012. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity
14. Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis. Semin. Nephrol. 30: 164-1762010.
15. Bouts, Y. M., D. F. Wolthuis, M. F. Dirkx, et al. 2012. Apoptosis and NET formation in the pathogenesis of SLE. Autoimmunity. 45: 597-601
16. Garcia-Romo, G. S., S. Caielli, B. Vega, et al. 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra20
17. Hakkim, A., B. G. Furnrohr, K. Amann, et al. 2010. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA. 107: 9813-9818
18. Lande, R., D. Ganguly, V. Facchinetti, et al. 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra19
19. Mjelle, J. E., O. P. Rekvig, J. Van Der Vlag, and K. A. Fenton 2011. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal crossreactive antigens. Autoimmunity. 44: 373-383
20. Radic, M., M. Herrmann, J. van der Vlag, and O. P. Rekvig. 2011. Regulatory and pathogenetic mechanisms of autoantibodies in SLE. Autoimmunity. 44: 349-356
21. Villanueva, E., S. Yalavarthi, C. C. Berthier, et al. 2011. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187: 538-552
22. Appel, G. B., G. Contreras, M. A. Dooley, et al. 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20: 1103-1112
23. Chan, T. M., F. K. Li, C. S. Tang, et al. 2000. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343: 1156-1162
24. Cordeiro, A. C., and D. A. Isenberg. 2008. Novel therapies in lupus-focus on nephritis. Acta. Reumatol. Port. 33: 157-169
25. Jonsdottir, T., I. Gunnarsson, A. F. Mourao, et al. 2010. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology. (Oxford) 49: 1502-1504
26. Rivera, T. L., H. M. Belmont, S. Malani, et al. 2009. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J. Rheumatol. 36: 298-305
27. Atisha-Fregoso, Y., J. Jakez-Ocampo, and L. Llorente. 2011. Systemic lupus erythematosus in Hispanics. Autoimmunity. 44: 555-561
28. Cooper, G. S., E. L. Treadwell, E. W. St Clair, et al. 2007. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum. 57: 993-999 (Pubitemid 47237325)
29. Mok, C. C. 2005. Prognostic factors in lupus nephritis. Lupus. 14: 39-44 (Pubitemid 40216066)
30. Patel, M., A. M. Clarke, I. N. Bruce, and D. P. Symmons. 2006. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 54: 2963-2969 (Pubitemid 44497777)
31. Tan, E. M., A. S. Cohen, J. F. Fries, et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277 (Pubitemid 13221242)
32. Austin 3rd, H. A., L. R. Muenz, K. M. Joyce, et al. 1984. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25: 689-695 (Pubitemid 14079965)
33. Cross, J., A. Dwomoa, P. Andrews, et al. 2005. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron. Clin. Pract. 100: c92-c100 (Pubitemid 40868991)
34. Ginzler, E. M., M. A. Dooley, C. Aranow, et al. 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353: 2219-2228 (Pubitemid 41697285)
35. Ferrario, L., M. Bellone, E. Bozzolo, et al. 2000. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology. (Oxford) 39: 218-220 (Pubitemid 30139363)
36. Bertsias, G. K., M. Tektonidou, Z. Amoura, et al. 2012. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71: 1771-1782
37. Miyakis, S., M. D. Lockshin, T. Atsumi, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4: 295-306
38. Saxena, R., T. Mahajan, and C. Mohan. 2011. Lupus nephritis: current update. Arthritis Res. Ther. 13: 240
39. Austin 3rd, H. A., D. T. Boumpas, E. M. Vaughan, and J. E. Balow 1995. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol. Dial. Transplant. 10: 1620-1628
40. Burgos, P. I., G. McGwin Jr, G. J. Pons-Estel, et al. 2011. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann. Rheum. Dis. 70: 393-394
41. Burling, F., J. Ng, H. Thein, et al. 2007. Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort. Lupus. 16: 830-837 (Pubitemid 350069798)
42. Mok, C. C. 2010. Racial difference in the prognosis of lupus nephritis. Nephrology. (Carlton) 15: 480-481
43. Font, J., R. Cervera, M. Ramos-Casals, et al. 2004. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin. Arthritis Rheum. 33: 217-230 (Pubitemid 38280821)
44. Houssiau, F. A., C. Vasconcelos, D. D'Cruz, et al. 2002. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46: 2121-2131
45. Cameron, J. S. 1999. Lupus nephritis: an historical perspective 1968-1998. J. Nephrol. 12: S29-S41
46. Contreras, G., O. Lenz, V. Pardo, et al. 2006. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 69: 1846-1851 (Pubitemid 43739214)
47. Al Arfaj, A. S., N. Khalil, and Al Saleh S. 2009. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol. Int. 29: 1057-1067
48. Alamanos, Y., P. V. Voulgari, C. Siozos, et al. 2003. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. J Rheumatol 30: 731-735 (Pubitemid 36402765)
49. Huong, D. L., T. Papo, H. Beaufils, et al. 1999. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine. (Baltimore) 78: 148-166 (Pubitemid 29231142)
50. Seligman, V. A., R. F. Lum, J. L. Olson, et al. 2002. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am. J. Med. 112: 726-729 (Pubitemid 34655662)
51. Houssiau, F. A., C. Vasconcelos, D. D'Cruz, et al. 2004. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50: 3934-3940 (Pubitemid 39643941)
52. MacGowan, J. R., S. Ellis, M. Griffiths, and D. A. Isenberg. 2002. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology. (Oxford) 41: 981-987
53. Korbet, S. M., E. J. Lewis, M. M. Schwartz, et al. 2000. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am. J. Kidney Dis. 35: 904-914 (Pubitemid 30238204)
54. Levey, A. S., S. P. Lan, H. L. Corwin, et al. 1992. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann. Intern. Med. 116: 114-123
55. El Hachmi, M., M. Jadoul, C. Lefebvre, et al. 2003. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus. 12: 692-696 (Pubitemid 37173666)
56. Illei, G. G., K. Takada, D. Parkin, et al. 2002. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46: 995-1002 (Pubitemid 34303812)
57. Bradshaw, S. E. 2011. Lupus nephritis: sustained proteinuria and dyslipidemia are risk factors for progressive CKD in patients with lupus nephritis. Nat. Rev. Nephrol. 7: 184
58. Reich, H. N., D. D. Gladman, M. B. Urowitz, et al. 2011. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int. 79: 914-920
59. Laoprasopwattana, K., P. Dissaneewate, and P. Vachvanichsanong 2009. Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide. Pediatr. Nephrol. 24: 1337-1343
60. Canti, V., M. T. Castiglioni, S. Rosa, et al. 2012. Pregnancy outcomes in patients with systemic autoimmunity. Autoimmunity
61. Blumenfeld, Z., D. Shapiro, M. Steinberg, et al. 2000. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 9: 401-405 (Pubitemid 30487421)
62. Harward, L. E., K. Mitchell, C. Pieper, et al. 2013. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 22: 81-86
63. Huong, D. L., Z. Amoura, P. Duhaut, et al. 2002. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J. Rheumatol. 29: 2571-2576 (Pubitemid 35416964)
64. McDermott, E. M., and R. J. Powell. 1996. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann. Rheum. Dis. 55: 224-229 (Pubitemid 26122247)
65. Park, M. C., Y. B. Park, S. Y. Jung, et al. 2004. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus
66. Somers, E. C., W. Marder, G. M. Christman, et al. 2005. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 52: 2761-2767 (Pubitemid 41369104)
67. Hahn, B. H., M. A. McMahon, A. Wilkinson, et al. 2012. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care. Res. (Hoboken) 64: 797-808